These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 33775904)

  • 1. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
    Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
    Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
    BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
    Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N
    Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma.
    Carpagnano GE; Resta E; Povero M; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Barbaro MPF
    Sci Rep; 2021 Mar; 11(1):5453. PubMed ID: 33750842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma.
    García-Mochón L; Gil-Sierra MD; Alegre-Del Rey EJ; Alarcón de la Lastra-Romero C; Sánchez-Hidalgo M
    Farm Hosp; 2019 Nov; 43(6):187-193. PubMed ID: 31705642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
    Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
    J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
    Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
    Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States.
    Settipane RA; Kreindler JL; Chung Y; Tkacz J
    Ann Allergy Asthma Immunol; 2019 Dec; 123(6):564-572.e3. PubMed ID: 31494235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Impact of Asthma Biologics: A Nationwide US Claim-Based Analysis.
    Al-Shaikhly T; Norris MR; Dennis EH; Liu G; Craig TJ
    J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1558-1567. PubMed ID: 38423294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
    Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease burden in patients with asthma before initiating biologics: A retrospective cohort database study.
    Ortega H; Hahn B; Tran JN; Bell C; Shams SA; Llanos JP
    Allergy Asthma Proc; 2019 May; 40(3):146-153. PubMed ID: 30925945
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland.
    Jahnz-Różyk K; Lis J; Warchoł M; Kucharczyk A
    BMC Pulm Med; 2018 Mar; 18(1):48. PubMed ID: 29548318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic burden of uncontrolled severe noneosinophilic asthma.
    Tan L; Reibman J; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
    Am J Manag Care; 2022 Jun; 28(6):e212-e220. PubMed ID: 35738228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain.
    Vennera Mdel C; Valero A; Uría E; Forné C; Picado C
    Clin Drug Investig; 2016 Jul; 36(7):567-78. PubMed ID: 27142072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
    Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
    J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.
    Lafeuille MH; Dean J; Zhang J; Duh MS; Gorsh B; Lefebvre P
    Ann Allergy Asthma Immunol; 2012 Jul; 109(1):59-64. PubMed ID: 22727159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
    Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
    J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.